Johnson and Johnson 2010 Annual Report Download - page 6

Download and view the complete annual report

Please find page 6 of the 2010 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

JOHNSON & JOHNSON 2010 ANNUAL REPORT4
the most significant need.
In Oncology, Velcade* (bortezomib), for multiple myeloma,
grew 16 percent operationally while eclipsing $1 billion in sales
outside the U.S. for the first time.
In addition, we continue to pursue line extensions.
We submitted applications for several major line extensions,
among them REMICADE® and SIMPONI®, which continue
to build the strength of our Immunology franchise.
Over the next three years, we expect to file compounds to
address critical medical needs, including Alzheimer’s disease and
diabetes, conditions growing in prevalence as the population
ages. With five compounds currently in registration and several
more planned in the coming years, our portfolio ranks among the
leaders in the industry. Our pipeline meets unmet needs and
features many true innovations designed to change the treatment
paradigm for patients.
MEDICAL DEVICES AND DIAGNOSTICS
The Medical Devices and Diagnostics (MD&D) franchises
comprise the world’s largest medical technology business, with
sales of $24.6 billion, an increase of approximately 3 percent
operationally. Despite the economic slowdown, which led to a
decline in surgical procedures and pricing pressures across the
business, we achieved growth in six of our seven franchises, as
well as in all regions.
Our MD&D businesses advanced a very strong pipeline,
completed and integrated several acquisitions, and aggressively
expanded into emerging markets. The segment maintained or
improved market share in the majority of its largest product
platforms, despite intense competition.
For example, the Ethicon franchise grew 8 percent
operationally, based on its strong suite of surgical products, as
well as recent acquisitions in new markets like aesthetics and ear,
nose and throat surgery. The Ethicon Endo-Surgery franchise
grew 5 percent operationally. Double-digit growth in its advanced
sterilization products and energy products were major
contributors. Our Vision Care franchise had operational sales
growth of 4 percent based on its core ACUVUE® Brand Contact
Lens and the continued launch of 1-DAY ACUVUE® TruEye™
Contact Lenses into new markets. The Ortho Clinical Diagnostics
franchise grew 4 percent operationally with the continued growth
of the VITROS® 3600 and 5600 analyzers.
The DePuy franchise increased operational sales by 3 percent
based on the strength of its orthopaedic reconstruction, sports
medicine and neurological businesses. Diabetes Care increased
operational sales by 2 percent with the introduction of a number
of new OneTouch® products around the world. Meanwhile,
sales in the Cordis franchise continued to decline due to competi-
tion in drug-eluting stents. This was partially offset by the strong
growth of electrophysiology products in the Biosense Webster
business, which grew nearly 20 percent operationally for the year.
CONSUMER
Consumer sales were $14.6 billion, a decline of approximately
9 percent operationally. Sales were impacted by McNeil recalls, as
well as the general economic slowdown and greater consumer
sensitivity to spending, reflected in a broad move towards store
* Velcade is a trademark of Millennium Pharmaceuticals, Inc.
* Operational excludes the impact of currency
Medical Devices and Diagnostics
Segment Sales
Sales by Major Franchise (in billions of dollars)
2010 Sales: $24.6 billion
Sales Change
Total: 4.4%
Operational*: 3.4%
MD&D
DEPUY®
$5.6
4.0%
ETHICON
ENDO-SURGERY®
$4.8
5.9%
DIABETES
CARE
$2.5
1.2%
ORTHO-CLINICAL
DIAGNOSTICS®
$2.0
4.6%
VISION
CARE
$2.7
6.9%
CORDIS®
$2.5
(4.7%)
ETHICON®
$4.5
9.2%
Pharm
Pharmaceutical Segment Sales
Sales by Major Product (in billions of dollars)
2010 Sales: $22.4 billion
Sales Change
Total: (0.6%)
Operational*: (1.0%)
LEVAQUIN®/
FLOXIN®
$1.4
(12.5%)
PROCRIT®/
EPREX®
$1.9
(13.9%)
OTHER
$9.1
6.6%
CONCERTA®
$1.3
(0.5%)
REMICADE®
$4.6
7.1%
RISPERDAL®
CONSTA®
$1.5
5.3%
TOPAMAX®
$0.5
(53.3%)
VELCADE®
$1.1
15.8%
ACIPHEX®/
PARIET®
$1.0
(8.2%)
Consumer Segment Sales
Sales by Major Franchise (in billions of dollars)
2010 Sales: $14.6 billion
Sales Change
Total: (7.7%)
Operational*: (8.9%)
BABY CARE
$2.2
4.4% SKIN CARE
$3.5
(0.4%)
WOUND
CARE/
OTHER
$1.0
(10.4%)
OTC
PHARMACEUTICALS
& NUTRITIONALS
$4.6
(19.2%)
ORAL CARE
$1.5
(2.7%)
Consumer
WOMEN’S
HEALTH
$1.8
(2.7%)